NCT05046678

Brief Summary

It has been stated that microRNA (miRNA) play an important role in development, homeostasis and immune functions, and abnormal miRNA expression may cause faster disease progression. The aim of this study was to determine miR-203, miR-142-3p, miR-146a, miR-146b, miR-155, miR-29b gene expressions in saliva of the patients with periodontal disease before and after non-surgical periodontal therapy (NSPT) and to evaluate the effect of smoking on these miRNAs. A total of 90 individuals, 30 with periodontitis, 30 with gingivitis, and 30 periodontally healthy (control group), were included. These three groups were divided into subgroups as smoking and non-smoking individuals, with 15 people in each group. NSPT was applied to patients with periodontitis and gingivitis. Saliva samples and clinical parameters were taken from at baseline and repeated 6 weeks after NSPT.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

September 13, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 16, 2021

Completed
Last Updated

September 16, 2021

Status Verified

September 1, 2021

Enrollment Period

6 months

First QC Date

September 13, 2021

Last Update Submit

September 13, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • miRNAs gene expressions in the periodontal disease

    miR-203, miR-142-3p, miR-146a, miR-146b, miR-155, miR-29b gene expressions in saliva

    baseline

Secondary Outcomes (1)

  • miRNAs gene expressions in the periodontal disease

    baseline and 6 weeks after treatment

Other Outcomes (1)

  • miRNAs gene expressions in the periodontal disease

    baseline and 6 weeks after treatment

Study Arms (6)

Control

Periodontally healthy, non-smoking

Diagnostic Test: Smokers with periodontally healthyDiagnostic Test: Non-smokers with gingivitisDiagnostic Test: Smokers with gingivitisDiagnostic Test: Non-smokers with periodontitisDiagnostic Test: Smokers with periodontitis

Smokers with periodontally healthy

Periodontally healthy, smoking

Diagnostic Test: ControlDiagnostic Test: Non-smokers with gingivitisDiagnostic Test: Smokers with gingivitisDiagnostic Test: Non-smokers with periodontitisDiagnostic Test: Smokers with periodontitis

Non-smokers with gingivitis

Gingivitis, non-smoking

Diagnostic Test: ControlDiagnostic Test: Smokers with periodontally healthyDiagnostic Test: Smokers with gingivitisDiagnostic Test: Non-smokers with periodontitisDiagnostic Test: Smokers with periodontitis

Smokers with gingivitis

Gingivitis, smoking

Diagnostic Test: ControlDiagnostic Test: Smokers with periodontally healthyDiagnostic Test: Non-smokers with gingivitisDiagnostic Test: Non-smokers with periodontitisDiagnostic Test: Smokers with periodontitis

Non-smokers with periodontitis

Periodontitis, non-smoking

Diagnostic Test: ControlDiagnostic Test: Smokers with periodontally healthyDiagnostic Test: Non-smokers with gingivitisDiagnostic Test: Smokers with gingivitisDiagnostic Test: Smokers with periodontitis

Smokers with periodontitis

Periodontitis, smoking

Diagnostic Test: ControlDiagnostic Test: Smokers with periodontally healthyDiagnostic Test: Non-smokers with gingivitisDiagnostic Test: Smokers with gingivitisDiagnostic Test: Non-smokers with periodontitis

Interventions

ControlDIAGNOSTIC_TEST

probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking

Non-smokers with gingivitisNon-smokers with periodontitisSmokers with gingivitisSmokers with periodontally healthySmokers with periodontitis

probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years

ControlNon-smokers with gingivitisNon-smokers with periodontitisSmokers with gingivitisSmokers with periodontitis

without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking

ControlNon-smokers with periodontitisSmokers with gingivitisSmokers with periodontally healthySmokers with periodontitis

without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years

ControlNon-smokers with gingivitisNon-smokers with periodontitisSmokers with periodontally healthySmokers with periodontitis

interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and nonsmokers if they had no previous history of smoking

ControlNon-smokers with gingivitisSmokers with gingivitisSmokers with periodontally healthySmokers with periodontitis

interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years

ControlNon-smokers with gingivitisNon-smokers with periodontitisSmokers with gingivitisSmokers with periodontally healthy

Eligibility Criteria

Age25 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

1. group (Control): Periodontally and systemically healthy and non-smoking 2. group: Periodontally and systemically healthy and smoking 3. group: Gingivitis, Systemically healthy and non-smoking 4. group: Gingivitis, Systemically healthy and smoking 5. group: Periodontitis, Systemically healthy and non-smoking 6. group: Periodontitis, Systemically healthy and smoking

You may qualify if:

  • Have at least 20 natural teeth, excluding third molars. Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations.
  • Gingivitis patients had without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the entire mouth Periodontally healthy control group had no sign of gingival inflammation, no PD \> 3mm and no evidence of attachment or bone loss

You may not qualify if:

  • History of systemic disease. Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study.
  • Periodontal treatment during last 6 months that could affect periodontal status.
  • History of radiotherapy or chemotherapy. Current pregnancy, lactation or menopause.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ordu University

Ordu, In the USA Or Canada, Please Select..., 52100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Periodontal DiseasesPeriodontitisGingivitis

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic DiseasesInfectionsGingival Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
6 Weeks
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
T.C. ORDU ÜNİVERSİTESİ

Study Record Dates

First Submitted

September 13, 2021

First Posted

September 16, 2021

Study Start

March 1, 2019

Primary Completion

September 1, 2019

Study Completion

November 1, 2020

Last Updated

September 16, 2021

Record last verified: 2021-09

Locations